Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 8/20 | 0.66 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24723416 | 0.97 | HTR1A (0.70) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL24723279 | 0.89 | HTR2A (0.59) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL32669456 | 0.87 | HTR2A (0.63) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL29992645 | 0.85 | HTR2A (0.60) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL25253115 | 0.84 | HTR2A (0.62) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL26508426 | 0.82 | HTR2A (0.71) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL25293651 | 0.82 | HTR2A (0.64) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL30777162 | 0.82 | HTR2A (0.56) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL27084736 | 0.82 | HTR2A (0.62) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL25245158 | 0.81 | HTR2A (0.61) | HTR1AHTR2AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | TPH2, TPH1, HTR2A | HTR1A 6/4885HTR2A 3/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.